Ocular Therapeutix, Inc. (OCUL) vs Stoke Therapeutics, Inc. (STOK)
A side-by-side comparison of Ocular Therapeutix, Inc. and Stoke Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OCUL
Ocular Therapeutix, Inc.
$7.35HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
STOK
Stoke Therapeutics, Inc.
$24.15HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
Total return — OCUL vs STOK
growth of $100 · dividends reinvested · last 7yOCUL +61.8% (+7.1%/yr)STOK -1.0% (-0.1%/yr)OCUL compounded faster over this window
OCUL STOK
OCUL vs STOK: by the numbers
- •OCUL is the larger company ($1.61B vs $1.56B market cap).
- •Both run net losses; OCUL's is the smaller (-579.10% vs -753.60% net margin).
Metrics side by side
Valuation
| Metric | OCUL | STOK |
|---|---|---|
| P/S ratio | 30.90 | 56.47 |
| P/B ratio | 3.09 | 4.51 |
Profitability
| Metric | OCUL | STOK |
|---|---|---|
| Gross margin | 87.11% | 100.00% |
| Operating margin | -521.04% | -11.16% |
| Net margin | -579.10% | -753.60% |
| ROE | -57.97% | -60.17% |
| ROIC | -50.20% | -63.12% |
Growth (annualized)
| Metric | OCUL | STOK |
|---|---|---|
| Revenue CAGR (5Y) | 10.03% | N/A |
| Total return CAGR (5Y) | -5.73% | -0.24% |
Frequently asked
- How have OCUL and STOK total returns compared?
- Over the past 5 years, OCUL delivered -5.73% and STOK delivered -0.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.